WO2006017317A3 - Method for the treatment of disease - Google Patents

Method for the treatment of disease Download PDF

Info

Publication number
WO2006017317A3
WO2006017317A3 PCT/US2005/024755 US2005024755W WO2006017317A3 WO 2006017317 A3 WO2006017317 A3 WO 2006017317A3 US 2005024755 W US2005024755 W US 2005024755W WO 2006017317 A3 WO2006017317 A3 WO 2006017317A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
cancers
mutation
disorders
diseases
Prior art date
Application number
PCT/US2005/024755
Other languages
French (fr)
Other versions
WO2006017317A2 (en
Inventor
Andrea I Mcclatchey
Marcello Curto
Original Assignee
Gen Hospital Corp
Andrea I Mcclatchey
Marcello Curto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Andrea I Mcclatchey, Marcello Curto filed Critical Gen Hospital Corp
Publication of WO2006017317A2 publication Critical patent/WO2006017317A2/en
Publication of WO2006017317A3 publication Critical patent/WO2006017317A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides novel methods for the treatment or prevention of diseases and disorders, e.g., cancer, characterized by a mutation in the Nf2 gene. In this method, one or more compounds that inhibit signaling through the EGFR is administered to an individual with Nf2 mutation. In a preferred embodiment the one or more compound is an EGFR inhibitor. Diseases and disorders such as neurofibromatosis type 2 (NF-2) and cancers such as, but not limited to cancers of the nervous system (e.g., Schwann cell tumors, 5-schwannoma, meningioma, or ependymoma) and malignant mesothelioma are treatable by the methods of the present invention.
PCT/US2005/024755 2004-07-12 2005-07-12 Method for the treatment of disease WO2006017317A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58720104P 2004-07-12 2004-07-12
US60/587,201 2004-07-12

Publications (2)

Publication Number Publication Date
WO2006017317A2 WO2006017317A2 (en) 2006-02-16
WO2006017317A3 true WO2006017317A3 (en) 2006-03-30

Family

ID=35839794

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/024755 WO2006017317A2 (en) 2004-07-12 2005-07-12 Method for the treatment of disease

Country Status (1)

Country Link
WO (1) WO2006017317A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2629244C (en) 2005-11-11 2014-08-05 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
SI2068880T1 (en) * 2006-09-18 2012-08-31 Boehringer Ingelheim Int Method for treating cancer harboring egfr mutations
ES2731901T3 (en) 2009-07-06 2019-11-19 Boehringer Ingelheim Int Process for drying BIBW2992, its salts and solid pharmaceutical formulations comprising this active ingredient
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102685A1 (en) * 2000-07-06 2002-08-01 Boehringer Ingelheim International Gmbh Novel use of inhibitors of the epidermal growth factor receptor
US20030232741A1 (en) * 2002-05-06 2003-12-18 Washington University Methods of treatment of glaucoma and other conditions mediated by NOS-2 expression via inhibition of the EGFR pathway

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102685A1 (en) * 2000-07-06 2002-08-01 Boehringer Ingelheim International Gmbh Novel use of inhibitors of the epidermal growth factor receptor
US20030232741A1 (en) * 2002-05-06 2003-12-18 Washington University Methods of treatment of glaucoma and other conditions mediated by NOS-2 expression via inhibition of the EGFR pathway

Also Published As

Publication number Publication date
WO2006017317A2 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
WO2004039774A3 (en) Mitotic kinesin inhibitors
WO2003099211A3 (en) Mitotic kinesin inhibitors
WO2003049678A3 (en) Mitotic kinesin inhibitors
WO2003050064A3 (en) Mitotic kinesin inhibitors
WO2003049527A3 (en) Mitotic kinesin inhibitors
WO2003049679A3 (en) Mitotic kinesin inhibitors
WO2003050122A3 (en) Mitotic kinesin inhibitors
WO2004037171A3 (en) Mitotic kinesin inhibitors
WO2005017190A3 (en) Mitotic kinesin inhibitors
WO2003039460A3 (en) Mitotic kinesin inhibitors
WO2004058148A3 (en) Mitotic kinesin inhibitors
IL165624A0 (en) Mitotic kinesin inhibitors
WO2003079973A3 (en) Mitotic kinesin inhibitors
WO2006044860A3 (en) Thiadiazole compounds and methods of use
WO2004058176A3 (en) Acyclic pyrazole compounds
WO2005018547A3 (en) Mitotic kinesin inhibitors
WO2004058700A3 (en) Mitotic kinesin inhibitors
HRP20090195T1 (en) Mitotic kinesin inhibitors
WO2006034154A3 (en) Salts of 5-azacytidine
WO2005065183A3 (en) Mitotic kinesin inhibitors
WO2003097835A3 (en) Pharmaceutical compositions for the treatment of cancer
PL1732926T3 (en) Mitotic kinesin inhibitors
WO2006031348A3 (en) Mitotic kinesin inhibitors
WO2005044201A3 (en) Ph sensitive prodrugs of 2,6-diisopropylphenol
WO2006017317A3 (en) Method for the treatment of disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase